Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1998 1
2000 1
2001 1
2002 1
2003 1
2004 3
2005 4
2006 1
2007 2
2013 3
2014 4
2015 2
2016 5
2017 4
2018 4
2019 3
2020 1
2021 6
2022 7
2023 4
2024 10
2025 4
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Results by year

Filters applied: . Clear all
Page 1
Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study.
Morschhauser F, Dahiya S, Palomba ML, Martin Garcia-Sancho A, Reguera Ortega JL, Kuruvilla J, Jäger U, Cartron G, Izutsu K, Dreyling M, Kahl B, Ghesquieres H, Ardeshna K, Goto H, Barbui AM, Abramson JS, Borchmann P, Fleury I, Mielke S, Skarbnik A, de Vos S, Kamdar M, Karmali R, Viardot A, Farazi T, Fasan O, Lymp J, Vedal M, Nishii R, Avilion A, Papuga J, Kumar J, Nastoupil LJ. Morschhauser F, et al. Among authors: barbui am. Nat Med. 2024 Aug;30(8):2199-2207. doi: 10.1038/s41591-024-02986-9. Epub 2024 Jun 3. Nat Med. 2024. PMID: 38830991 Free PMC article. Clinical Trial.
Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM).
Perico N, Remuzzi G, Griffin MD, Cockwell P, Maxwell AP, Casiraghi F, Rubis N, Peracchi T, Villa A, Todeschini M, Carrara F, Magee BA, Ruggenenti PL, Rota S, Cappelletti L, McInerney V, Griffin TP, Islam MN, Introna M, Pedrini O, Golay J, Finnerty AA, Smythe J, Fibbe WE, Elliman SJ, O'Brien T; NEPHSTROM Trial Consortium. Perico N, et al. J Am Soc Nephrol. 2023 Oct 1;34(10):1733-1751. doi: 10.1681/ASN.0000000000000189. Epub 2023 Aug 10. J Am Soc Nephrol. 2023. PMID: 37560967 Free PMC article. Clinical Trial.
Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
Hiddemann W, Barbui AM, Canales MA, Cannell PK, Collins GP, Dürig J, Forstpointner R, Herold M, Hertzberg M, Klanova M, Radford J, Seymour JF, Tobinai K, Trotman J, Burciu A, Fingerle-Rowson G, Wolbers M, Nielsen T, Marcus RE. Hiddemann W, et al. Among authors: barbui am. J Clin Oncol. 2018 Aug 10;36(23):2395-2404. doi: 10.1200/JCO.2017.76.8960. Epub 2018 Jun 1. J Clin Oncol. 2018. PMID: 29856692 Clinical Trial.
A Multicenter Real-life Prospective Study of Axicabtagene Ciloleucel versus Tisagenlecleucel Toxicity and Outcomes in Large B-cell Lymphomas.
Stella F, Chiappella A, Casadei B, Bramanti S, Ljevar S, Chiusolo P, Di Rocco A, Tisi MC, Carrabba MG, Cutini I, Martino M, Dodero A, Bonifazi F, Santoro A, Sorà F, Botto B, Barbui AM, Russo D, Musso M, Grillo G, Krampera M, Olivieri J, Ladetto M, Cavallo F, Massaia M, Arcaini L, Pennisi M, Zinzani PL, Miceli R, Corradini P. Stella F, et al. Among authors: barbui am. Blood Cancer Discov. 2024 Sep 3;5(5):318-330. doi: 10.1158/2643-3230.BCD-24-0052. Blood Cancer Discov. 2024. PMID: 38953781 Free PMC article.
Outcomes of CAR T-cell therapy in high-grade B-cell lymphomas compared to DLBCL: a weighted comparison analysis.
Dodero A, Ceparano G, Casadei B, Angelillo P, Bramanti S, Tisi MC, Ljevar S, Stella F, Chiappella A, Botto B, Cutini I, Zanirato G, Chiusolo P, Barbui AM, Farina M, Di Rocco A, Grillo G, Olivieri J, Krampera M, Ladetto M, Guidetti A, Zinzani PL, Carniti C, Corradini P. Dodero A, et al. Among authors: barbui am. Blood Adv. 2025 Dec 23;9(24):6491-6501. doi: 10.1182/bloodadvances.2025016117. Blood Adv. 2025. PMID: 40763273 Free PMC article.
Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study.
Chiappella A, Casadei B, Chiusolo P, Di Rocco A, Ljevar S, Magni M, Angelillo P, Barbui AM, Cutini I, Dodero A, Bonifazi F, Tisi MC, Bramanti S, Musso M, Farina M, Martino M, Novo M, Grillo G, Patriarca F, Zacchi G, Krampera M, Pennisi M, Galli E, Martelli M, Ferreri AJM, Ferrari S, Saccardi R, Bermema A, Guidetti A, Miceli R, Zinzani PL, Corradini P. Chiappella A, et al. Among authors: barbui am. Leukemia. 2024 May;38(5):1107-1114. doi: 10.1038/s41375-024-02213-x. Epub 2024 Mar 8. Leukemia. 2024. PMID: 38459167 Free PMC article.
Prospective Validation of CAR-HEMATOTOX and a Simplified Version Predict Survival in Patients with Large B-Cell Lymphoma Treated with Anti-CD19 CAR T-Cells: Data from CART-SIE Study.
Stella F, Pennisi M, Chiappella A, Casadei B, Bramanti S, Ljevar S, Chiusolo P, Rocco AD, Tisi MC, Angelillo P, Cutini I, Martino M, Barone A, Bonifazi F, Santoro A, Sorà F, Novo M, Barbui AM, Russo D, Musso M, Grillo G, Krampera M, Olivieri J, Brunello L, Cavallo F, Massaia M, Arcaini L, Farina L, Zinzani P, Miceli R, Corradini P. Stella F, et al. Among authors: barbui am. Transplant Cell Ther. 2025 Apr;31(4):240.e1-240.e9. doi: 10.1016/j.jtct.2025.01.888. Epub 2025 Jan 25. Transplant Cell Ther. 2025. PMID: 39870308 Free article.
Brexucabtagene autoleucel in-vivo expansion and BTKi refractoriness have a negative influence on progression-free survival in mantle cell lymphoma: Results from CART-SIE study.
Stella F, Chiappella A, Magni M, Bonifazi F, De Philippis C, Musso M, Cutini I, Ljevar S, Barbui AM, Farina M, Martino M, Massaia M, Grillo G, Angelillo P, Botto B, Patriarca F, Krampera M, Arcaini L, Tisi MC, Zinzani P, Sorà F, Bramanti S, Pennisi M, Carniti C, Corradini P. Stella F, et al. Among authors: barbui am. Br J Haematol. 2025 Feb;206(2):644-651. doi: 10.1111/bjh.19961. Epub 2024 Dec 22. Br J Haematol. 2025. PMID: 39710966 Free PMC article.
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study.
Palomba ML, Schuster SJ, Karmali R, Skarbnik AP, Abramson JS, Ardeshna K, Borchmann P, Hill BT, García-Sancho AM, Marcacci G, Rapoport AP, Cartron G, Fleury I, Izutsu K, Kamdar M, Mielke S, Barbui AM, Ortega JLR, Nastoupil LJ, Ahmed S, Bar M, Diaz L, Furustrand U, Diab V, Vedal M, Avilion A, Kumar J, Nishii R, Colicino S, Morschhauser F. Palomba ML, et al. Among authors: barbui am. Lancet. 2026 Mar 7;407(10532):963-975. doi: 10.1016/S0140-6736(25)02435-3. Epub 2026 Feb 12. Lancet. 2026. PMID: 41692020 Clinical Trial.
70 results